Thyroseq testing
Ended Awarded Last action
- Contract number
- HT001422F0077
- Awardee
-
Cytopath Biopsy Lab Inc. UEI KC5VWAGMNLT6
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $148,142
Award facts
- Contract value 100% obligated
- $148,142.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 621511 Medical Laboratories
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Port Chester, NY 10573, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$61,858 | |
| Original award | $210,000 |
About this award
This is a contract award to Cytopath Biopsy Lab Inc. (doing business as Cblpath) by the Defense Health Agency for ThyroSeq genetic testing services. Cytopath Biopsy Lab is a provider of specialized anatomic pathology and molecular diagnostic laboratory services, with a focus on cancer screening and diagnosis utilizing next-generation genomic sequencing.
The $148,142.40 firm fixed price contract is for the provision of ThyroSeq testing, which involves analyzing genetic mutations to evaluate the malignancy of thyroid nodules. This contract is not a set-aside and has a period of performance through February 12, 2024.
Cytopath Biopsy Lab has previously provided similar ThyroSeq testing services to the Department of Veterans Affairs and Walter Reed National Military Medical Center to support thyroid cancer screening and diagnosis for veterans and active military personnel. The company holds several Indefinite Delivery/Indefinite Quantity (IDIQ) contract vehicles and Blanket Purchase Agreements (BPAs) with the VA and Defense Health Agency to deliver these specialized molecular diagnostic testing services on an as-needed basis.
Quick answers
Who was awarded contract HT001422F0077?
HT001422F0077 was awarded to Cytopath Biopsy Lab Inc. by Defense Health Agency (Department of Defense) on February 17, 2022.
How much is contract HT001422F0077 worth?
The government has obligated $148,142 on HT001422F0077.
Is contract HT001422F0077 an order under another contract?
Yes. HT001422F0077 is a BPA call under HT001419A0011, a blanket purchase agreement.
Was contract HT001422F0077 competed?
The extent of competition for HT001422F0077 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award